Precigen 2025 Q3 Earnings Record Revenue Amid 510.3% Wider Net Loss

Precigen (PGEN) delivered a mixed Q3 2025 performance, with revenue exceeding expectations but net losses widening sharply. The company reported $2.92 million in revenue, a 206.9% year-over-year increase, driven by robust collaboration and licensing income. However, net losses expanded to $146.34 million, a 510.3% increase from 2024 Q3, as the CEO emphasized strategic priorities for PAPZIMEOS commercialization and regulatory expansion.

Revenue

Precigen’s revenue surged to $2.92 million in Q3 2025, a 206.9% increase from $952,000 in the prior-year period. This growth was primarily fueled by a 946.9% rise in collaboration and licensing revenues, which accounted for $1.82 million of total revenue. Product revenues contributed $162,000, while service revenues added $942,000, reflecting expanded commercial activities post-FDA approval of PAPZIMEOS. The company’s focus on strategic partnerships and therapeutic commercialization underpinned the strong top-line performance.

Earnings/Net Income

Precigen’s losses deepened to $1.06 per share in Q3 2025, a 1,077.8% increase in losses compared to $0.09 per share in 2024 Q3. The net loss widened to $146.34 million, a 510.3% year-over-year increase, driven by elevated selling, general, and administrative (SG&A) expenses and R&D costs. Despite record revenue, the EPS performance remains a critical concern for investors.

Price Action

The stock price of Precigen surged 28.31% during the latest trading day, 24.36% during the most recent full trading week, and 37.39% month-to-date. This sharp rally followed the Q3 earnings report and broader market optimism around PAPZIMEOS commercialization.

Post-Earnings Price Action Review

Precigen’s stock has experienced a dramatic post-earnings rally, with a 37.39% month-to-date surge and a 28.31% single-day gain. The stock’s performance reflects investor enthusiasm for the company’s FDA-approved PAPZIMEOS therapy and its potential to dominate the RRP treatment market. While the widened net loss raises concerns, the rapid adoption of PAPZIMEOS—including over 100 patients registered in the Patient Hub and 90% of target institutions engaged—has driven speculative momentum. Analysts remain divided, with some citing valuation risks but others highlighting the drug’s transformative potential and geographic expansion plans.

CEO Commentary

Helen Sabzevari, CEO, emphasized PAPZIMEOS’s “monumental turning point” status in RRP treatment, citing its 51% complete response rate and 86% reduction in surgical burden. Strategic priorities include advancing pediatric trials, securing EMA approval, and leveraging redosing potential. The leadership team expressed confidence in commercial momentum, noting rapid formulary adoption and payer coverage for 80 million lives.

Guidance

Harry Thomasian, CFO, outlined expectations for cash breakeven by year-end 2026, supported by $124 million in cash reserves. The company anticipates “high teens to low 20%” gross-to-net revenue adjustments and plans to share Q4 patient dosing data. Phil Tennant highlighted durability data from 3-year follow-ups to strengthen payer negotiations.

Additional News

Citizens reiterated an $8.00 price target for Precigen following the Q3 results, maintaining its “Market Outperform” rating. The stock, trading at $3.86, has surged 337% year-to-date. Separately, Precigen announced a $125 million non-dilutive financing plan to support operations, addressing liquidity concerns. The company also submitted a marketing authorization application with the EMA, signaling intentions for European expansion.